688289 圣湘生物
已收盘 11-19 15:00:00
资讯
新帖
简况
圣湘生物“二次创业”一年半:第二业绩增长点难挽狂澜,实控人下场增持股票
时代周报 · 11-09
圣湘生物“二次创业”一年半:第二业绩增长点难挽狂澜,实控人下场增持股票
圣湘生物大幅上涨 获主力净流入831万元
智选洞察 · 11-07
圣湘生物大幅上涨 获主力净流入831万元
圣湘生物大幅上涨 获主力净流入1172万元
智选洞察 · 11-01
圣湘生物大幅上涨 获主力净流入1172万元
圣湘生物大跌5.10% 3家券商给予增持建议
智选洞察 · 10-30
圣湘生物大跌5.10% 3家券商给予增持建议
圣湘董事长,出手9651万!
IVD资讯 · 10-29
圣湘董事长,出手9651万!
圣湘生物、三诺生物等5家医疗器械公司发布三季报,仅1家实现净利润增长
中国制药网 · 10-24
圣湘生物、三诺生物等5家医疗器械公司发布三季报,仅1家实现净利润增长
图解圣湘生物三季报:第三季度单季净利润同比减81.39%
证券之星 · 10-24
图解圣湘生物三季报:第三季度单季净利润同比减81.39%
圣湘生物:持续高速增长 期待呼吸道检测业务“旺季”表现
国投证券 · 10-24
圣湘生物:持续高速增长 期待呼吸道检测业务“旺季”表现
圣湘生物最新公告:前三季度净利润同比下降34.80%
证券之星 · 10-23
圣湘生物最新公告:前三季度净利润同比下降34.80%
圣湘生物(688289.SH)发前三季业绩,净利润1.95亿元,同比减少34.80%
智通财经 · 10-23
圣湘生物(688289.SH)发前三季业绩,净利润1.95亿元,同比减少34.80%
多领域快速放量,圣湘生物前三季扣非净利增超六倍
证券之星 · 10-23
多领域快速放量,圣湘生物前三季扣非净利增超六倍
圣湘生物:2024年前三季度净利润约1.95亿元
每日经济新闻 · 10-23
圣湘生物:2024年前三季度净利润约1.95亿元
圣湘生物涨5.92%,华鑫证券二个月前给出“买入”评级
证券之星 · 10-23
圣湘生物涨5.92%,华鑫证券二个月前给出“买入”评级
圣湘生物大幅上涨 获融资净买入1208万元
智选洞察 · 10-23
圣湘生物大幅上涨 获融资净买入1208万元
科技打头阵,如何低门槛布局科创板?
博时基金 · 10-22
科技打头阵,如何低门槛布局科创板?
圣湘生物10月18日主力资金流入630万元 连续5日加仓
市场透视 · 10-18
圣湘生物10月18日主力资金流入630万元 连续5日加仓
圣湘生物股价大幅上涨 郑州金水产业投资基金合伙企业备案
智选洞察 · 10-18
圣湘生物股价大幅上涨 郑州金水产业投资基金合伙企业备案
圣湘生物(688289.SH)产品取得医疗器械注册证
智通财经 · 10-17
圣湘生物(688289.SH)产品取得医疗器械注册证
圣湘生物最新公告:副流感病毒1、2、3型核酸检测试剂盒取得医疗器械注册证
证券之星 · 10-17
圣湘生物最新公告:副流感病毒1、2、3型核酸检测试剂盒取得医疗器械注册证
圣湘生物10月16日获主力加仓664万元 环比增加477.39%
市场透视 · 10-16
圣湘生物10月16日获主力加仓664万元 环比增加477.39%
暂无数据
公司概况
公司名称:
圣湘生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-08-28
主营业务:
圣湘生物科技股份有限公司的主营业务为以自主创新基因技术为核心,集诊断试剂和仪器的研发、生产、销售,以及第三方医学检验服务于一体的体外诊断整体解决方案,其主要产品为病毒性肝炎系列产品、生殖道感染与遗传系列产品、儿科感染系列产品、呼吸道感染系列产品、核酸血液筛查系列产品、科研、公共卫生、动物疫病系列产品、核酸提取系列产品、生化系列产品、全自动核酸检测反应体系构建系列产品、POCT移动分子诊断系统系列产品、荧光PCR检测分析软件、第三方医学检验服务、科研服务。
发行价格:
50.48
{"stockData":{"symbol":"688289","market":"SH","secType":"STK","nameCN":"圣湘生物","latestPrice":22.89,"timestamp":1731999600000,"preClose":22,"halted":0,"volume":7921477,"delay":0,"floatShares":582000000,"shares":582000000,"eps":0.4455,"marketStatus":"已收盘","marketStatusCode":5,"change":0.89,"latestTime":"11-19 15:00:00","open":22.17,"high":23,"low":21.93,"amount":177000000,"amplitude":0.0486,"askPrice":22.9,"askSize":281,"bidPrice":22.89,"bidSize":26,"shortable":0,"etf":0,"ttmEps":0.4455,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":22,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":24.2,"lowLimit":19.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":582388006,"pbRate":1.84,"roa":"--","roe":"2.69%","epsLYR":0.62,"committee":-0.820707,"marketValue":13331000000,"floatMarketCap":13331000000,"peRate":51.380473,"changeRate":0.0405,"turnoverRate":0.0136,"status":0,"afterMarket":{"amount":0,"volume":0,"close":22.89,"buyVolume":0,"sellVolume":0,"time":1732001639464,"indexStatus":"已收盘 11-19 15:30:00","preClose":22}},"requestUrl":"/m/hq/s/688289/tweets","defaultTab":"tweets","newsList":[{"id":"2482496247","title":"圣湘生物“二次创业”一年半:第二业绩增长点难挽狂澜,实控人下场增持股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2482496247","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482496247?lang=zh_cn&edition=full","pubTime":"2024-11-09 11:30","pubTimestamp":1731123001,"startTime":"0","endTime":"0","summary":"10月28日,圣湘生物发布公告称实控人戴立忠将增持股票。2023年4月,为减少对新冠核酸检测试剂业务的依赖,圣湘生物提出要寻找第二业绩增长点,主力产品为呼吸道病原体诊断。二次创业一年半,第二业绩增长点仍难力挽狂澜2020年初,圣湘生物新型冠状病毒核酸检测试剂盒通过药监局的审批,成为国内较早获批的企业。随后,2023年4月,圣湘生物披露2022年财报的同时,提出“二次创业”的口号,称将寻找第二业绩增长点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109113108abaf91b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109113108abaf91b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161022","688289","BK0239"],"gpt_icon":0},{"id":"2481913383","title":"圣湘生物大幅上涨 获主力净流入831万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481913383","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481913383?lang=zh_cn&edition=full","pubTime":"2024-11-07 10:52","pubTimestamp":1730947922,"startTime":"0","endTime":"0","summary":"11月07日,圣湘生物股价大幅上涨,截至10点52分,圣湘生物上涨5.00%,报23.94元/股,成交1.21亿元,换手率0.89%。资金动向截止发稿,圣湘生物获得主力净流入831万元,其中超大单流入846万元,大单流出15万元。最新财报显示,今年三季报,圣湘生物实现营业收入10.33亿元,同比增长63.24%,净利润为1.95亿元,同比减少34.80%,基本每股收益为0.34元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107105224aba8361f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107105224aba8361f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2480604005","title":"圣湘生物大幅上涨 获主力净流入1172万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480604005","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480604005?lang=zh_cn&edition=full","pubTime":"2024-11-01 13:05","pubTimestamp":1730437547,"startTime":"0","endTime":"0","summary":"11月01日,圣湘生物股价大幅上涨,截至13点05分,圣湘生物上涨5.08%,报23.60元/股,成交1.77亿元,换手率1.34%,振幅6.37%。资金动向截止发稿,圣湘生物获得主力净流入1172万元,其中超大单流入339万元,大单流入832万元。最新财报显示,今年三季报,圣湘生物实现营业收入10.33亿元,同比增长63.24%,净利润为1.95亿元,同比减少34.80%,基本每股收益为0.34元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101130705ab8fec4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101130705ab8fec4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2479245332","title":"圣湘生物大跌5.10% 3家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2479245332","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479245332?lang=zh_cn&edition=full","pubTime":"2024-10-30 13:28","pubTimestamp":1730266104,"startTime":"0","endTime":"0","summary":"10月30日,圣湘生物股价大幅下跌,截至13点28分,圣湘生物下跌5.10%,报22.50元/股,成交2.53亿元,换手率1.87%。此外,数据统计显示,近半年内3家券商给予增持建议,16家券商给予买入建议。资金动向截止发稿,圣湘生物获得主力净流出2817万元,其中超大单流出1244万元,大单流出1571万元。最新财报显示,今年三季报,圣湘生物实现营业收入10.33亿元,同比增长63.24%,净利润为1.95亿元,同比减少34.80%,基本每股收益为0.34元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030132842a1f7e1ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030132842a1f7e1ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2479445595","title":"圣湘董事长,出手9651万!","url":"https://stock-news.laohu8.com/highlight/detail?id=2479445595","media":"IVD资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479445595?lang=zh_cn&edition=full","pubTime":"2024-10-29 13:22","pubTimestamp":1730179379,"startTime":"0","endTime":"0","summary":"基于对公司未来发展的信心和对公司长期投资价值的认可,自2021年起,戴立忠先生已披露并持续履行两份增持计划,截至本公告披露日,已累计增持公司股份 2,241,481 股,均通过集中竞价交易方式进行,合计增持金额 9,651.34 万元。圣湘生物2024年前三季报显示,公司主营收入10.33亿元,同比上升63.24%;归母净利润1.95亿元,同比下降34.8%;扣非净利润1.51亿元,同比上升637.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029133405a1f41f02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029133405a1f41f02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2477422573","title":"圣湘生物、三诺生物等5家医疗器械公司发布三季报,仅1家实现净利润增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2477422573","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477422573?lang=zh_cn&edition=full","pubTime":"2024-10-24 14:34","pubTimestamp":1729751657,"startTime":"0","endTime":"0","summary":"上市 医疗器械 公司三季报正陆续披露。10月24日,有5家发布成绩单,分别是 圣湘生物 、 三诺生物 、 港通医疗 、 凯利泰 和 福瑞股份 ,从净利润变动情况来看,仅1家实现净利润增长,即福瑞股份。另外4家医疗器械公司前三季度均有所承压。信达证券 表示,10月份医疗上市公司将陆续披露2024年三季报,短期或可关注业绩有望超预期的个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024143809ab6f6353&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024143809ab6f6353&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300298","688289","159883"],"gpt_icon":0},{"id":"2477590885","title":"图解圣湘生物三季报:第三季度单季净利润同比减81.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477590885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477590885?lang=zh_cn&edition=full","pubTime":"2024-10-24 00:36","pubTimestamp":1729701399,"startTime":"0","endTime":"0","summary":"证券之星消息,圣湘生物2024年三季报显示,公司主营收入10.33亿元,同比上升63.24%;归母净利润1.95亿元,同比下降34.8%;扣非净利润1.51亿元,同比上升637.21%;其中2024年第三季度,公司单季度主营收入3.16亿元,同比上升54.08%;单季度归母净利润3872.12万元,同比下降81.39%;单季度扣非净利润3019.25万元,同比上升383.38%;负债率14.21%,投资收益-2861.41万元,财务费用-6026.32万元,毛利率77.5%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400000264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289"],"gpt_icon":0},{"id":"2477547661","title":"圣湘生物:持续高速增长 期待呼吸道检测业务“旺季”表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2477547661","media":"国投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477547661?lang=zh_cn&edition=full","pubTime":"2024-10-24 00:00","pubTimestamp":1729699200,"startTime":"0","endTime":"0","summary":"事件:圣湘生物发布2024 年三季度业绩报告收入上公司延续了上半年的高速增长态势。单三季度,公司毛利率达到78.04%,与同为呼吸道检测淡季的二季度相比提升了5.37pct。多款新品获批,看好四季度呼吸道业务进展。进入10 月以来,院端ILI%开始震荡抬升,国内或进入呼吸道传染病高发季节,看好公司在第四季度延续前三季度的良好态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410241156219f58a79e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410241156219f58a79e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2477534653","title":"圣湘生物最新公告:前三季度净利润同比下降34.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477534653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477534653?lang=zh_cn&edition=full","pubTime":"2024-10-23 22:51","pubTimestamp":1729695061,"startTime":"0","endTime":"0","summary":"圣湘生物公布2024年第三季度报告,公司前三季度实现营业收入10.33亿元,同比增长63.24%;净利润1.95亿元,同比下降34.80%。第三季度实现营业收入3.16亿元,同比增长54.08%;净利润3872.12万元,同比下降81.39%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300038281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289"],"gpt_icon":0},{"id":"2477588903","title":"圣湘生物(688289.SH)发前三季业绩,净利润1.95亿元,同比减少34.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477588903","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477588903?lang=zh_cn&edition=full","pubTime":"2024-10-23 19:21","pubTimestamp":1729682478,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣湘生物(688289.SH)发布2024年前三季度报告,报告期内公司实现营业收入10.33亿元,同比增长63.24%;归属于上市公司股东的净利润1.95亿元,同比减少34.80%;归属于上市公司股东扣除非经常性损益净利润1.51亿元,同比增长637.21%;基本每股收益0.34元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688289"],"gpt_icon":0},{"id":"2477685588","title":"多领域快速放量,圣湘生物前三季扣非净利增超六倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2477685588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477685588?lang=zh_cn&edition=full","pubTime":"2024-10-23 19:07","pubTimestamp":1729681679,"startTime":"0","endTime":"0","summary":"积极加码生态圈建设,创新驱动战略成效凸显,圣湘生物三季度扣非净利增超六倍。10月23日晚,圣湘生物披露2024年度三季报,呼吸道、妇幼、血源、测序及免疫等多个关键领域开拓蓝海,取得长足发展。据统计,2020年以来,圣湘生物累计研发投入金额已达10.79亿元。此次呼吸道领域数智化大会的参与跨度与影响力之广,也标志着行业内部对圣湘生物这一发展战略的高度认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024102300032180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2477300990","title":"圣湘生物:2024年前三季度净利润约1.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477300990","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477300990?lang=zh_cn&edition=full","pubTime":"2024-10-23 19:03","pubTimestamp":1729681420,"startTime":"0","endTime":"0","summary":"每经AI快讯,圣湘生物(SH 688289,收盘价:22.19元)10月23日晚间发布三季度业绩公告称,2024年前三季度营收约10.33亿元,同比增加63.24%;归属于上市公司股东的净利润约1.95亿元,同比减少34.8%;基本每股收益0.34元,同比减少33.33%。截至发稿,圣湘生物市值为129亿元。道达号(daoda1997)“个股趋势”提醒:1. 近30日内无机构对圣湘生物进行调研。每经头条(nbdtoutiao)——罕见天文大潮来袭!从南到北多个省份突发海水倒灌,有车辆被淹,房屋进水,气象专家:国内外尚未发现明确记载!(记者 贾运可)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241023190447a1e3a8e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241023190447a1e3a8e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289"],"gpt_icon":0},{"id":"2477372895","title":"圣湘生物涨5.92%,华鑫证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477372895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477372895?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:11","pubTimestamp":1729671079,"startTime":"0","endTime":"0","summary":"今日圣湘生物涨5.92%,收盘报22.19元。2024年8月19日,华鑫证券研究员胡博新发布了对圣湘生物的研报《公司事件点评报告:延续高增长趋势》,该研报对圣湘生物给出“买入”评级。此外,华安证券研究员谭国超,李婵,中邮证券研究员蔡明子近期也对该股发布了研报,同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300025880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","161027"],"gpt_icon":0},{"id":"2477334916","title":"圣湘生物大幅上涨 获融资净买入1208万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477334916","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477334916?lang=zh_cn&edition=full","pubTime":"2024-10-23 10:40","pubTimestamp":1729651236,"startTime":"0","endTime":"0","summary":"10月23日,圣湘生物股价大幅上涨,截至10点40分,圣湘生物上涨5.11%,报22.02元/股,成交1.57亿元,换手率1.25%,振幅4.92%。资金动向截止发稿,圣湘生物获得主力净流入849万元,其中超大单流出21万元,大单流入871万元。融资融券方面,圣湘生物10月21日获得融资净买入1208万元,当日该股融资余额为2.70亿元,当较前一日增加4.68%;该股融券余额为62万元,融券余量为2.84万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241023104042a1e2f9dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241023104042a1e2f9dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵,如何低门槛布局科创板?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告,业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户,且满足交易风险评级要求,即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688327","688276","688062","688172","688005","688548","688106","688200","688347","688153","688433","688484","688789","688248","688409","688608","688029","688063","688088","688232","688266","688498","688556","688400","688336","688146","688048","688110","688778","688050","688567","688278","688520","688739","688578","688439","688612","688568","688390","688352","688582","688037","688052","688100","688032","688166","688007","688772","588030","688702","688055","688027","688798","688017","688575","688617","688083","688213","688526","688147","688387","688443","688549","688333","688001","688425","688192","159982","688639","688208","688139","688516","688343","688322","688006","688289","688097","688177","688700","688066","688019","688348","688366","688361","688235","000698","688281","688717","688016","688141","688107","688161","688408","688105","688331","688432","688318","688686","688690","688002","688536","688779","688326","688198"],"gpt_icon":0},{"id":"2476476063","title":"圣湘生物10月18日主力资金流入630万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2476476063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476476063?lang=zh_cn&edition=full","pubTime":"2024-10-18 15:18","pubTimestamp":1729235918,"startTime":"0","endTime":"0","summary":"10月18日, 圣湘生物股价涨7.48%,报收20.97元,成交金额2.42亿元,换手率2.02%,振幅11.94%,量比1.90。圣湘生物今日主力资金净流入630万元,连续5日净流入,上一交易日主力净流入928万元,今日环比减少32.11%。该股近5个交易日上涨4.80%,主力资金累计净流入2561万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流出5190万元,其中净流出天数为10日。该行业中净流入前三个股分别为迈瑞医疗、新产业、联影医疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101815293595b183c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101815293595b183c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2476144084","title":"圣湘生物股价大幅上涨 郑州金水产业投资基金合伙企业备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2476144084","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476144084?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:15","pubTimestamp":1729228541,"startTime":"0","endTime":"0","summary":"10月18日,圣湘生物股价大幅上涨,截至13点15分,圣湘生物上涨5.43%,报20.57元/股,突破20元整数关口,成交9976万元,换手率0.86%,振幅6.05%。主营业务及业绩圣湘生物公司主营业务为自主创新基因技术为核心,集诊断试剂和仪器的研发、生产、销售,以及第三方医学检验服务。最新财报显示,今年中报,圣湘生物实现营业收入7.17亿元,同比增长67.63%,净利润为1.57亿元,同比增长70.93%,基本每股收益为0.27元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018132830ab6b09f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018132830ab6b09f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2476614341","title":"圣湘生物(688289.SH)产品取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2476614341","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476614341?lang=zh_cn&edition=full","pubTime":"2024-10-17 18:52","pubTimestamp":1729162374,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣湘生物 公告,公司的产品副流感病毒1、2、3型核酸检测试剂盒于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。据悉,副流感病毒是引起婴幼儿、免疫抑制患者、老年人及合并慢性疾病患者呼吸道感染的重要病原体,可导致多种呼吸道疾病,包括普通感冒、中耳炎、哮吼、毛细支气管炎和肺炎等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK0239","BK1583","09997","BK1574","159883","688289","09996","BK1100"],"gpt_icon":1},{"id":"2476143115","title":"圣湘生物最新公告:副流感病毒1、2、3型核酸检测试剂盒取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2476143115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476143115?lang=zh_cn&edition=full","pubTime":"2024-10-17 18:50","pubTimestamp":1729162251,"startTime":"0","endTime":"0","summary":"圣湘生物公告,公司产品副流感病毒1、2、3型核酸检测试剂盒(荧光PCR法)近日收到国家药品监督管理局颁发的《医疗器械注册证》。该产品用于定性检测咽拭子样本中的副流感病毒1型、2型和3型的核酸。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101700028186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239","09997","BK1583","BK1222","BK1574","09996","BK1100","159883"],"gpt_icon":0},{"id":"2475938058","title":"圣湘生物10月16日获主力加仓664万元 环比增加477.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475938058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475938058?lang=zh_cn&edition=full","pubTime":"2024-10-16 15:19","pubTimestamp":1729063164,"startTime":"0","endTime":"0","summary":"10月16日, 圣湘生物股价涨0.46%,报收19.71元,成交金额1.06亿元,换手率0.92%,振幅3.01%,量比0.59。圣湘生物今日主力资金净流入664万元,连续3日净流入,上一交易日主力净流入115万元,今日环比增加477.39%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为50.00%,平均涨幅为1.33%。该股近5个交易日下跌8.96%,主力资金累计净流入2191万元;近20日主力资金累计净流出6802万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101615350995ac2cce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101615350995ac2cce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-08-28","address":"湖南省长沙市岳麓区高新技术产业开发区麓松路680号","stockEarnings":[{"period":"1week","weight":-0.0749},{"period":"1month","weight":0.0491},{"period":"3month","weight":0.2036},{"period":"6month","weight":0.1113},{"period":"1year","weight":0.2799},{"period":"ytd","weight":0.1546}],"companyName":"圣湘生物科技股份有限公司","boardCode":"AI0027","perCapita":"29351股","boardName":"医药制造业","registeredCapital":"58238万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":" 圣湘生物科技股份有限公司的主营业务为以自主创新基因技术为核心,集诊断试剂和仪器的研发、生产、销售,以及第三方医学检验服务于一体的体外诊断整体解决方案,其主要产品为病毒性肝炎系列产品、生殖道感染与遗传系列产品、儿科感染系列产品、呼吸道感染系列产品、核酸血液筛查系列产品、科研、公共卫生、动物疫病系列产品、核酸提取系列产品、生化系列产品、全自动核酸检测反应体系构建系列产品、POCT移动分子诊断系统系列产品、荧光PCR检测分析软件、第三方医学检验服务、科研服务。","serverTime":1732009464403,"listedPrice":50.48,"stockholders":"19842人(较上一季度减少2.27%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣湘生物,688289,圣湘生物股票,圣湘生物股票老虎,圣湘生物股票老虎国际,圣湘生物行情,圣湘生物股票行情,圣湘生物股价,圣湘生物股市,圣湘生物股票价格,圣湘生物股票交易,圣湘生物股票购买,圣湘生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}